Published: Jan 2003
| ||Format||Pages||Price|| |
|PDF (3.0M)||20||$25||  ADD TO CART|
|Complete Source PDF (32M)||20||$154||  ADD TO CART|
BONE MORPHOGENETIC PROTEINS (BMPS) ARE GROWTH and differentiation factors originally isolated from bone matrix based on their ability to induce new bone formation in vivo, and form a large family of proteins structurally related to TGF-βs and activins. Recombinant human BMP, when implanted with an appropriate carrier matrix at defect sites, is capable of inducing new bone formation and restoring the lost bone by initiating a cellular process that mirrors embryonic bone formation. BMP containing osteogenic devices have been shown to be efficacious for the treatment of delayed and non-union fractures of long bone and anterior inter-body fusions of the spine and have been found to be equivalent to that of autograft in prospective, randomized, controlled and multicentered clinical trials. Recently, regulatory agencies in USA, Europe, Canada, and Australia have approved BMP-7 (OP-1™) and BMP-2 (InFuse™) containing osteogenic devices as bone graft substitutes for the treatment of long bone fractures and inter-body fusions in the spine. BMP is the first recombinant protein approved for orthopedic use and thus offers significant promise in the field of regenerative medicine.
Orthopaedic Research Laboratory, Cell and Protein Therapeutic Division, Genzyme Corporation, Framingham, MA
Center for Tissue Regeneration and Repair, Department of Orthopaedic Surgery, School of Medicine, University of California at Davis, Sacramento, CA
Paper ID: MONO10068M